Literature DB >> 29662193

SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.

J Y Liu1,2, Q H Zeng3, P G Cao4, D Xie5,6, F Yang7, L Y He1,2, Y B Dai1,2, J J Li8, X M Liu9, H L Zeng10, X J Fan11, L Liu12, Y X Zhu4, L Gong4, Y Cheng13, J D Zhou8, J Hu14, H Bo15, Z Z Xu16, K Cao17.   

Abstract

Sperm-associated antigen 5 (SPAG5) is involved in various biological processes. However, the roles of SPAG5 in bladder urothelial carcinoma (BUC) are unknown. This study showed that upregulation of SPAG5 was detected frequently in primary BUC tissues, and was associated with significantly worse survival among the 112 patients that underwent radical cystectomy (RC). Up and downregulating the expression of SPAG5 enhanced or inhibited, respectively, the proliferation of BUC cells in vitro and in vivo, and suppressed or enhanced, respectively, apoptosis in vitro and in vivo. Moreover, SPAG5 increased the resistance of BUC cells to chemotherapy-induced apoptosis. Mechanistic investigations showed that SPAG5 promotes proliferation and suppresses apoptosis in BUC at least partially via upregulating Wnt3 through activating the AKT/mTOR signaling pathway. The importance of the SPAG5/AKT-mTOR/Wnt3 axis identified in BUC cell models was confirmed via immunohistochemical analysis of a cohort of human BUC specimens that underwent RC. Collectively, our data suggested that in patients with BUC who underwent RC, high SPAG5 expression is associated with poor survival. In addition, targeting SPAG5 might represent a novel therapeutic strategy to improve the survival of patients with BUC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29662193     DOI: 10.1038/s41388-018-0223-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

Review 1.  Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.

Authors:  Jeffrey J Leow; William Martin-Doyle; Padma S Rajagopal; Chirayu G Patel; Erin M Anderson; Andrew T Rothman; Richard J Cote; Yuksel Urun; Steven L Chang; Toni K Choueiri; Joaquim Bellmunt
Journal:  Eur Urol       Date:  2013-08-28       Impact factor: 20.096

2.  Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells.

Authors:  Kathrin Thedieck; Birgit Holzwarth; Mirja Tamara Prentzell; Christopher Boehlke; Kathrin Kläsener; Stefanie Ruf; Annika Gwendolin Sonntag; Lars Maerz; Sushma-Nagaraja Grellscheid; Elisabeth Kremmer; Roland Nitschke; E Wolfgang Kuehn; Johan W Jonker; Albert K Groen; Michael Reth; Michael N Hall; Ralf Baumeister
Journal:  Cell       Date:  2013-08-15       Impact factor: 41.582

3.  Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers.

Authors:  Kristjan Välk; Tõnu Vooder; Raivo Kolde; Mari-Ann Reintam; Cathleen Petzold; Jaak Vilo; Andres Metspalu
Journal:  Oncology       Date:  2011-03-16       Impact factor: 2.935

4.  Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.

Authors:  M K Siu; Y-C Tsai; Y-S Chang; J J Yin; F Suau; W-Y Chen; Y-N Liu
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

5.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

Authors:  J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal
Journal:  Eur Urol       Date:  2016-06-30       Impact factor: 20.096

6.  Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.

Authors:  Yair Lotan; Aditya Bagrodia; Niccolo Passoni; Varun Rachakonda; Payal Kapur; Yull Arriaga; Christian Bolenz; Vitaly Margulis; Ganesh V Raj; Arthur I Sagalowsky; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-04-03       Impact factor: 20.096

Review 7.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

8.  Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.

Authors:  Stéphanie Cornen; Arnaud Guille; José Adélaïde; Lynda Addou-Klouche; Pascal Finetti; Marie-Rose Saade; Marwa Manai; Nadine Carbuccia; Ismahane Bekhouche; Anne Letessier; Stéphane Raynaud; Emmanuelle Charafe-Jauffret; Jocelyne Jacquemier; Salvatore Spicuglia; Hugues de The; Patrice Viens; François Bertucci; Daniel Birnbaum; Max Chaffanet
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

9.  SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.

Authors:  L-J Yuan; J-D Li; L Zhang; J-H Wang; T Wan; Y Zhou; H Tu; J-P Yun; R-Z Luo; W-H Jia; M Zheng
Journal:  Cell Death Dis       Date:  2014-05-22       Impact factor: 8.469

10.  The landscape of candidate driver genes differs between male and female breast cancer.

Authors:  Ida Johansson; Markus Ringnér; Ingrid Hedenfalk
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more
  15 in total

1.  Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.

Authors:  Valeria Canu; Sara Donzelli; Andrea Sacconi; Federica Lo Sardo; Claudio Pulito; Noa Bossel; Anna Di Benedetto; Paola Muti; Claudio Botti; Eytan Domany; Silvio Bicciato; Sabrina Strano; Yosef Yarden; Giovanni Blandino
Journal:  Cell Death Differ       Date:  2020-11-23       Impact factor: 15.828

2.  Identification of Tissue-Specific Expressed Hub Genes and Potential Drugs in Rheumatoid Arthritis Using Bioinformatics Analysis.

Authors:  Xuewu Xing; Qun Xia; Baoqi Gong; Zhongyang Shen; Yingze Zhang
Journal:  Front Genet       Date:  2022-03-18       Impact factor: 4.599

3.  Micro RNA-363 inhibits esophageal squamous cell carcinoma progression by directly targeting sperm-associated antigen 5.

Authors:  Lingmin Zhang; Li Wang; Ning Lu; Jia Wang; Rong Yan; Honglin Yan; Jia Zhang; Mingxin Zhang
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

4.  Co-expression Network Analysis of Biomarkers for Adrenocortical Carcinoma.

Authors:  Lushun Yuan; Guofeng Qian; Liang Chen; Chin-Lee Wu; Han C Dan; Yu Xiao; Xinghuan Wang
Journal:  Front Genet       Date:  2018-08-15       Impact factor: 4.599

5.  SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.

Authors:  Ming Li; Anqi Li; Shuling Zhou; Hong Lv; Wentao Yang
Journal:  J Hematol Oncol       Date:  2019-02-08       Impact factor: 17.388

6.  KIF5A Promotes Bladder Cancer Proliferation In Vitro and In Vivo.

Authors:  Da-Wei Tian; Zhou-Liang Wu; Li-Ming Jiang; Jie Gao; Chang-Li Wu; Hai-Long Hu
Journal:  Dis Markers       Date:  2019-07-03       Impact factor: 3.434

7.  High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer.

Authors:  Mei Zhang; Ling Sha; Ning Hou; Chuanbing Shi; Lin Tan
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

Review 8.  Curcumin-A Viable Agent for Better Bladder Cancer Treatment.

Authors:  Jochen Rutz; Andrea Janicova; Katja Woidacki; Felix K-H Chun; Roman A Blaheta; Borna Relja
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

9.  SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.

Authors:  Hongliang Liu; Junwen Hu; Ran Wei; Longfei Zhou; Hua Pan; Hongchao Zhu; Mingwen Huang; Jun Luo; Wei Xu
Journal:  J Exp Clin Cancer Res       Date:  2018-09-18

10.  SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway.

Authors:  Jun Xu; Yujie Deng; Yi Wang; Xiaofang Sun; Shuqin Chen; Guoxiang Fu
Journal:  Cell Prolif       Date:  2020-01-19       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.